Literature DB >> 32538053

miR-142 is a Sensitive Biomarker for the Diagnosis and Prognosis of Acute Myocardial Infarction.

Zhongpu Chen, Xiaodong Pan, Gaoliang Yan, Zulong Sheng, Genshan Ma.   

Abstract

BACKGROUND: Acute myocardial infarction (AMI) is myocardial necrosis caused by acute and persistent ischemia and hypoxia of coronary arteries. AMI is one of the most common diseases in European countries and over 1.5 million AMI patients die of it in the United States annually. A collection of studies proposed that certain micro-RNAs play crucial roles in the onset and development of AMI.
METHODS: Ninety-four AMI patients and 83 non-AMI healthy controls were recruited from Zhongda Hospital, Southeast University between July 2015 and September 2017. Serum samples were collected at admission and the expression of miR-142 was detected using real-time quantitative polymerase chain reaction (RT-qPCR) assays.
RESULTS: miR-142 expression was markedly elevated in serum samples of AMI patients compared with the 83 non-AMI healthy controls. miR-142 expression was positively correlated with creatine kinase-KB (CK-MB; r = 0.6731, p = 0.0021) and troponin (r = 0.7138, p = 0.0013). The area under the curve (AUC) of miR-142, CK-MB, and troponin for the diagnosis of AMI were 0.9185, 0.8172, and 0.8717, respectively. Overall survival analysis implied that high miR-142 expression may predict poor survival (log-rank test, p = 0.0146).
CONCLUSIONS: miR-142 may be a diagnostic and prognostic indicator for AMI, and therefore, it may contribute to AMI clinicopathologic prediction.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32538053     DOI: 10.7754/Clin.Lab.2019.191019

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  1 in total

1.  Marathon-Induced Cardiac Strain as Model for the Evaluation of Diagnostic microRNAs for Acute Myocardial Infarction.

Authors:  Omid Shirvani Samani; Johannes Scherr; Elham Kayvanpour; Jan Haas; David H Lehmann; Weng-Tein Gi; Karen S Frese; Rouven Nietsch; Tobias Fehlmann; Steffi Sandke; Tanja Weis; Andreas Keller; Hugo A Katus; Martin Halle; Norbert Frey; Benjamin Meder; Farbod Sedaghat-Hamedani
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.